Archive

1.6 million UK adults used weight loss drugs in past year

Written by Charlie King | 12 Jan 2026

An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according… read more.

EMA teams up with influencers on weight loss drugs

Written by Gary Finnegan | 6 Dec 2025

The EU drug watchdog, the European Medicines Agency (EMA), has launched a partnership with social media influencers to promote the safe use of GLP-1 receptor agonists. The #HealthNotHype… read more.

GLP-1 agonists: Addressing side effects of weight loss drugs

Written by Charlie King | 24 Nov 2025

New research is uncovering how medications targeting the glucagon-like peptide-1 (GLP-1) system affect brain circuits involved in nausea, thirst, and pleasurable behaviors. These findings will be presented at… read more.

Half of people stop taking popular weight-loss drug within a year, national study finds

Written by Charlie King | 20 Sep 2025

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study being presented at… read more.

GLP-1 weight-loss drugs pose hidden risks for young women

Written by Charlie King | 17 Sep 2025

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers. A new study has… read more.

One in seven bariatric surgery patients turn to new weight loss drugs

Written by Charlie King | 31 Aug 2025

Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like… read more.

Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests

Written by Charlie King | 28 May 2025

Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research being presented at this year’s European Congress… read more.

What’s the mechanism behind behavioral side effects of popular weight loss drugs?

Written by Charlie King | 25 Jan 2025

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have… read more.

Despite heavy marketing, most Americans reject the new weight-loss drugs

Written by Charlie King | 10 Oct 2024

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such as Wegovy and Ozempic. The survey was conducted by Morning Consult… read more.

Archive

Subscribe for our mailing list

Follow Us